Compare · JNJ vs NGNE
JNJ vs NGNE
Side-by-side comparison of Johnson & Johnson (JNJ) and Neurogene Inc. (NGNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and NGNE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $603.27B, about 860.4x NGNE ($701.2M).
- Over the past year, JNJ is up 49.3% and NGNE is up 66.2% - NGNE leads by 16.9 points.
- Both names hit the wire about 10 times in the past 4 weeks.
- JNJ has more recent analyst coverage (25 ratings vs 7 for NGNE).
- Company
- Johnson & Johnson
- Neurogene Inc.
- Price
- $250.66+0.73%
- $36.59-1.84%
- Market cap
- $603.27B
- $701.2M
- 1M return
- +9.77%
- +15.26%
- 1Y return
- +49.34%
- +66.23%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 10
- 10
- Recent ratings
- 25
- 7
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- EVP, Global Corp Affairs Broadhurst Vanessa exercised 23,054 shares at a strike of $130.77 and sold $5,792,686 worth of shares (23,054 units at $251.27) (SEC Form 4)
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
- Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
- Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Latest NGNE
- President and CFO Cvijic Christine Mikail sold $173,375 worth of shares (4,800 units at $36.12) as part of a pre-agreed trading plan (SEC Form 4)
- Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- President and CFO Cvijic Christine Mikail sold $166,586 worth of shares (4,800 units at $34.71) as part of a pre-agreed trading plan (SEC Form 4)
- Neurogene Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Neurogene Inc.
- Neurogene Inc. Announces Pricing of $125 Million Public Offering
- SEC Form 424B5 filed by Neurogene Inc.
- Neurogene Inc. Announces Proposed Public Offering
- Neurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome